[…] the FSH Society has worked with the drug’s developer, Acceleron Pharma, to better understand how FSHD affects patients through a survey (see story here) as well as to educate patients […]
Update on Clinical Trial A083-02: a Phase 2 Clinical Study of ACE-083 in FSHD
2018 FSHD Connect preliminary agenda
We’re excited to share with you the preliminary agenda for our 2018 FSHD Connect conference, where a coalition of patient and families, top researchers and clinicians, and advocates will gather […]
Team FSHD Skyland Trail will compete in the 2019 Race Across America
From PRWeb FSHD Skyland Trail Cycling Team Logo The FSHD Society and Skyland Trail today announce that they are jointly entering an eight-person team in the 2019 Race Across America (RAAM) to raise funds […]
Dyne Therapeutics to support ReSolve study of FSHD
[…] natural history study designed to inform the development of therapies for facioscapulohumeral muscular dystrophy ( FSHD). ReSolve (Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD) is an observational study run […]
UCLA Health – Southern California’s Frontlines of FSHD Research
[…] in an outpatient building at UCLA Health’s Westwood hospitals is UCLA Neurology, home to ground-breaking FSHD Research. UCLA Health already ranks as the #1 hospital in California, and 4th […]